Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group

William R. Friedenberg, Martin S. Tallman, Isadore Brodsky, Elisabeth M. Paietta, Jacob M. Rowe, Sandra J. Lee, Kendrith M. Rowland, George W. Schnetzer, John C. Reed

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

Original languageEnglish (US)
Pages (from-to)813-819
Number of pages7
JournalLeukemia Research
Volume28
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Multiple Drug Resistance
B-Cell Chronic Lymphocytic Leukemia
Apoptosis
P-Glycoproteins
R Factors
Vincristine
Therapeutics
Drug Resistance
Doxorubicin
Dexamethasone
valspodar

Keywords

  • Chronic lymphocytic leukemia
  • Multidrug resistance
  • p-Glycoprotein
  • PSC-833

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996) : A trial of the Eastern Cooperative Oncology Group. / Friedenberg, William R.; Tallman, Martin S.; Brodsky, Isadore; Paietta, Elisabeth M.; Rowe, Jacob M.; Lee, Sandra J.; Rowland, Kendrith M.; Schnetzer, George W.; Reed, John C.

In: Leukemia Research, Vol. 28, No. 8, 08.2004, p. 813-819.

Research output: Contribution to journalArticle

Friedenberg, William R. ; Tallman, Martin S. ; Brodsky, Isadore ; Paietta, Elisabeth M. ; Rowe, Jacob M. ; Lee, Sandra J. ; Rowland, Kendrith M. ; Schnetzer, George W. ; Reed, John C. / Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996) : A trial of the Eastern Cooperative Oncology Group. In: Leukemia Research. 2004 ; Vol. 28, No. 8. pp. 813-819.
@article{0707ed0885434cbf8a3ea92b25907321,
title = "Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group",
abstract = "Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21{\%}) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21{\%}) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.",
keywords = "Chronic lymphocytic leukemia, Multidrug resistance, p-Glycoprotein, PSC-833",
author = "Friedenberg, {William R.} and Tallman, {Martin S.} and Isadore Brodsky and Paietta, {Elisabeth M.} and Rowe, {Jacob M.} and Lee, {Sandra J.} and Rowland, {Kendrith M.} and Schnetzer, {George W.} and Reed, {John C.}",
year = "2004",
month = "8",
doi = "10.1016/j.leukres.2003.12.002",
language = "English (US)",
volume = "28",
pages = "813--819",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996)

T2 - A trial of the Eastern Cooperative Oncology Group

AU - Friedenberg, William R.

AU - Tallman, Martin S.

AU - Brodsky, Isadore

AU - Paietta, Elisabeth M.

AU - Rowe, Jacob M.

AU - Lee, Sandra J.

AU - Rowland, Kendrith M.

AU - Schnetzer, George W.

AU - Reed, John C.

PY - 2004/8

Y1 - 2004/8

N2 - Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

AB - Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

KW - Chronic lymphocytic leukemia

KW - Multidrug resistance

KW - p-Glycoprotein

KW - PSC-833

UR - http://www.scopus.com/inward/record.url?scp=2942622408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942622408&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.12.002

DO - 10.1016/j.leukres.2003.12.002

M3 - Article

C2 - 15203279

AN - SCOPUS:2942622408

VL - 28

SP - 813

EP - 819

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -